Dr Jess Haigh

BACKGROUND: Genes with multiple co-active promoters appear common in brain, yet little is known about functional requirements for these potentially redundant genomic regulatory elements. SCN1A, which encodes the NaV1.1 sodium channel alpha subunit, is one such gene with two co-active promoters. Mutations in SCN1A are associated with epilepsy, including Dravet syndrome (DS). The majority of DS patients harbor coding mutations causing SCN1A haploinsufficiency; however, putative causal non-coding promoter mutations have been identified. METHODS: To determine the functional role of one of these potentially redundant Scn1a promoters, we focused on the non-coding Scn1a 1b regulatory region, previously described as a non-canonical alternative transcriptional start site. We generated a transgenic mouse line with deletion of the extended evolutionarily conserved 1b non-coding interval and characterized changes in gene and protein expression, and assessed seizure activity and alterations in behavior. RESULTS: Mice harboring a deletion of the 1b non-coding interval exhibited surprisingly severe reductions of Scn1a and NaV1.1 expression throughout the brain. This was accompanied by electroencephalographic and thermal-evoked seizures, and behavioral deficits. CONCLUSIONS: This work contributes to functional dissection of the regulatory wiring of a major epilepsy risk gene, SCN1A. We identified the 1b region as a critical disease-relevant regulatory element and provide evidence that non-canonical and seemingly redundant promoters can have essential function.

The brain is responsible for maintaining whole-body energy homeostasis by changing energy input and availability. The hypothalamus and dorsal vagal complex (DVC) are the primary sites of metabolic control, able to sense both hormones and nutrients and adapt metabolism accordingly. The mitochondria respond to the level of nutrient availability by fusion or fission to maintain energy homeostasis; however, these processes can be disrupted by metabolic diseases including obesity and type II diabetes (T2D). Mitochondrial dynamics are crucial in the development and maintenance of obesity and T2D, playing a role in the control of glucose homeostasis and whole-body metabolism across neurons and glia in the hypothalamus and DVC.

Tracing of neurons plays an essential role in elucidating neural networks in the brain and spinal cord. Cholera toxin B subunit (CTB) is already widely used as a tracer although its use is limited by the need for immunohistochemical detection. A new construct incorporating non-canonical azido amino acids (azido-CTB) offers a novel way to expand the range and flexibility of this neuronal tracer. Azido-CTB can be detected rapidly in vivo following intramuscular tongue injection by ‘click’ chemistry, eliminating the need for antibodies. Cadmium selenide/zinc sulfide (CdSe/ZnS) core/shell nanoparticles were attached to azido-CTB by strain-promoted alkyne–azide cycloaddition to make a nano-conjugate. Following tongue injections the complex was detected in vivo in the brainstem by light microscopy and electron microscopy via silver enhancement. This method does not require membrane permeabilization and so ultrastructure is maintained. Azido-CTB offers new possibilities to enhance the utility of CTB as a neuronal tracer and delivery vehicle by modification using ‘click’ chemistry.

Enhancers are cis-regulatory elements that play critical regulatory roles in modulating developmental transcription programs and driving cell-type-specific and context-dependent gene expression in the brain. The development of massively parallel reporter assays (MPRAs) has enabled high-throughput functional screening of candidate DNA sequences for enhancer activity. Tissue-specific screening of in vivo enhancer function at scale has the potential to greatly expand our understanding of the role of non-coding sequences in development, evolution, and disease. Here, we adapted a self-transcribing regulatory element MPRA strategy for delivery to early postnatal mouse brain via recombinant adeno-associated virus (rAAV). We identified and validated putative enhancers capable of driving reporter gene expression in mouse forebrain, including regulatory elements within an intronic CACNA1C linkage disequilibrium block associated with risk in neuropsychiatric disorder genetic studies. Paired screening and single enhancer in vivo functional testing, as we show here, represents a powerful approach towards characterizing regulatory activity of enhancers and understanding how enhancer sequences organize gene expression in the brain.

A significant unmet need exists for the delivery of biologic drugs such as polypeptides or nucleic acids to the central nervous system for the treatment and understanding of neurodegenerative diseases. Naturally occurring bacterial toxins have been considered as tools to meet this need. However, due to the complexity of tethering macromolecular drugs to toxins and the inherent dangers of working with large quantities of recombinant toxins, no such route has been successfully exploited. Developing a method where a bacterial toxin’s nontoxic targeting subunit can be assembled with a drug immediately prior to in vivo administration has the potential to circumvent some of these issues. Using a phage-display screen, we identified two antibody mimetics, anticholera toxin Affimer (ACTA)-A2 and ACTA-C6 that noncovalently associate with the nonbinding face of the cholera toxin B-subunit. In a first step toward the development of a nonviral motor neuron drug-delivery vehicle, we show that Affimers can be selectively delivered to motor neurons in vivo.

ABSTRACT

A significant unmet need exists for the delivery of biologic drugs such as polypeptides or nucleic acids, to the central nervous system (CNS) for the treatment and understanding of neurodegenerative diseases. Naturally occurring toxoids have been considered as tools to meet this need. However, due to the complexity of tethering macromolecular drugs to toxins, and the inherent dangers of working with large quantities of recombinant toxin, no such route has been successfully exploited. Developing a method where toxoid and drug can be assembled immediately prior to in vivo administration has the potential to circumvent some of these issues. Using a phage-display screen, we identified two antibody mimetics, Anti-Cholera Toxoid Affimer (ACTA) -A2 and ACTA-C6 that non-covalently associate with the non-binding face of the cholera toxin B-subunit. In a first step toward the development of a non-viral motor neuron drug-delivery vehicle, we show that Affimers can be selectively delivered to motor neurons in vivo .

Gene regulation underlies the diversity in form and function of cell types in the brain. Here, we summarize the basic principles of gene regulatory networks that produce the dynamic expression patterns that distinguish neuronal cell types. We discuss the interplay between regulatory DNA, epigenetics, and relevant proteins and functional RNAs that determine transcriptional output. We present a perspective describing how gene regulatory networks are established that goes from early work defining major transcription factors controlling such networks to recent efforts to understand how such networks function at the molecular and genomic level. Finally, we provide examples of efforts to define the regulatory networks that drive neuronal differentiation and review emerging evidence for a critical role for mutations that perturb such regulatory networks in neurodevelopmental and neuropsychiatric disorders.

Gene regulation underlies the diversity in form and function of cell types in the brain. Here, we summarize the basic principles of gene regulatory networks that produce the dynamic expression patterns that distinguish neuronal cell types. We discuss the interplay between regulatory DNA, epigenetics, and relevant proteins and functional RNAs that determine transcriptional output. We present a perspective describing how gene regulatory networks are established that goes from early work defining major transcription factors controlling such networks to recent efforts to understand how such networks function at the molecular and genomic level. Finally, we provide examples of efforts to define the regulatory networks that drive neuronal differentiation and review emerging evidence for a critical role for mutations that perturb such regulatory networks in neurodevelopmental and neuropsychiatric disorders.

Effective assessment must demonstrate an effect - robust understanding of a subject. Assessment design is key, but feedback is an important tool in supporting our students to achieve this, not just after summative assessment, but throughout their learning journey. Often, student surveys report dissatisfaction with assessment and feedback. From a staff point of view there is frustration that the feedback provided, other than the mark itself, is often not used as it is intended as well as issues associated with assessment workload. So how do we approach solving these issues, especially in biomedical science where there is a range of subjects taught, by a number of different staff and both theoretical and practical elements? The first step is to consider assessment design. How can we produce assessments that are fit for purpose but are not onerous to mark? Secondly, how do we ensure that staff and students are on the same page when we talk about what feedback is and how it should be used? Finally, how do we integrate feedback throughout the learning journey, so it is effective not just for the current assessment but also for supporting achievement in future assessments?.